PCM
DTIL icon

Prelude Capital Management’s Precision BioSciences DTIL Stock Holding History

Prelude Capital Management’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-53
Closed -$13K – 1987
2019
Q3 		$13K Buy
+53
New +$17.3K ﹤0.01% 1454

Other funds holding DTIL

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
ACWM
Adams Chetwood Wealth Management Durham, North Carolina $176M AUM 8.48% 1-Year Est. Return

Prelude Capital Management's DTIL Position: Q4 2019 in Review

Prelude Capital Management sold out of Precision BioSciences (DTIL) in Q4 2019, closing a stake of 53 shares — an estimated $13K sold.

Prelude Capital Management first reported a position in DTIL in Q3 2019 and held it in 1 quarter. The position peaked at $13K in Q3 2019. 95 funds tracked by Wall St. Rank hold DTIL as of Q4 2019.

  • Prelude Capital Management reported no remaining Precision BioSciences position as of Q4 2019 after selling out during the quarter.
  • Prelude Capital Management sold 53 Precision BioSciences shares in Q4 2019, an estimated $13K.
  • Prelude Capital Management first reported a position in Precision BioSciences in Q3 2019 and held it in 1 quarter.
  • Prelude Capital Management's Precision BioSciences position peaked at $13K in Q3 2019.
  • 95 funds tracked by Wall St. Rank held Precision BioSciences as of Q4 2019.

Based on Prelude Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.